162 related articles for article (PubMed ID: 22617492)
1. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists.
Jiang R; Song X; Bali P; Smith A; Bayona CR; Lin L; Cameron MD; McDonald PH; Kenny PJ; Kamenecka TM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3890-4. PubMed ID: 22617492
[TBL] [Abstract][Full Text] [Related]
2. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
3. Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.
Stasi LP; Artusi R; Bovino C; Buzzi B; Canciani L; Caselli G; Colace F; Garofalo P; Giambuzzi S; Larger P; Letari O; Mandelli S; Perugini L; Pucci S; Salvi M; Toro P
Bioorg Med Chem Lett; 2013 May; 23(9):2653-8. PubMed ID: 23535328
[TBL] [Abstract][Full Text] [Related]
4. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.
Fujimoto T; Kunitomo J; Tomata Y; Nishiyama K; Nakashima M; Hirozane M; Yoshikubo S; Hirai K; Marui S
Bioorg Med Chem Lett; 2011 Nov; 21(21):6414-6. PubMed ID: 21917455
[TBL] [Abstract][Full Text] [Related]
6. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
Roecker AJ; Coleman PJ
Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats.
Whitman DB; Cox CD; Breslin MJ; Brashear KM; Schreier JD; Bogusky MJ; Bednar RA; Lemaire W; Bruno JG; Hartman GD; Reiss DR; Harrell CM; Kraus RL; Li Y; Garson SL; Doran SM; Prueksaritanont T; Li C; Winrow CJ; Koblan KS; Renger JJ; Coleman PJ
ChemMedChem; 2009 Jul; 4(7):1069-74. PubMed ID: 19418500
[TBL] [Abstract][Full Text] [Related]
8. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.
Perrey DA; German NA; Gilmour BP; Li JX; Harris DL; Thomas BF; Zhang Y
J Med Chem; 2013 Sep; 56(17):6901-16. PubMed ID: 23941044
[TBL] [Abstract][Full Text] [Related]
9. Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists.
Fujimoto T; Tomata Y; Kunitomo J; Hirozane M; Marui S
Bioorg Med Chem Lett; 2011 Nov; 21(21):6409-13. PubMed ID: 21924608
[TBL] [Abstract][Full Text] [Related]
10. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
Coleman PJ; Cox CD; Roecker AJ
Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
[TBL] [Abstract][Full Text] [Related]
11. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists.
Sifferlen T; Boss C; Cottreel E; Koberstein R; Gude M; Aissaoui H; Weller T; Gatfield J; Brisbare-Roch C; Jenck F
Bioorg Med Chem Lett; 2010 Mar; 20(5):1539-42. PubMed ID: 20144866
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.
Coleman PJ; Schreier JD; McGaughey GB; Bogusky MJ; Cox CD; Hartman GD; Ball RG; Harrell CM; Reiss DR; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2311-5. PubMed ID: 20207138
[TBL] [Abstract][Full Text] [Related]
13. Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692).
Christopher JA; Congreve MS
Expert Opin Ther Pat; 2013 Feb; 23(2):273-7. PubMed ID: 23282091
[TBL] [Abstract][Full Text] [Related]
14. Biomedical application of orexin/hypocretin receptor ligands in neuroscience.
Boss C; Brisbare-Roch C; Jenck F
J Med Chem; 2009 Feb; 52(4):891-903. PubMed ID: 19199652
[No Abstract] [Full Text] [Related]
15. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.
Malherbe P; Borroni E; Gobbi L; Knust H; Nettekoven M; Pinard E; Roche O; Rogers-Evans M; Wettstein JG; Moreau JL
Br J Pharmacol; 2009 Apr; 156(8):1326-41. PubMed ID: 19751316
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.
Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
Bioorg Med Chem Lett; 2013 Apr; 23(7):2212-6. PubMed ID: 23434414
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
20. Orexin receptor antagonists: a new concept in CNS disorders?
Gatfield J; Brisbare-Roch C; Jenck F; Boss C
ChemMedChem; 2010 Aug; 5(8):1197-214. PubMed ID: 20544785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
